| Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. C Sachse, J Brockmöller, S Bauer, I Roots American journal of human genetics 60 (2), 284, 1997 | 1349 | 1997 |
| Functional significance of a C→ A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine C Sachse, J Brockmöller, S Bauer, I Roots British journal of clinical pharmacology 47 (4), 445-449, 1999 | 954 | 1999 |
| A viral microRNA functions as an orthologue of cellular miR-155 E Gottwein, N Mukherjee, C Sachse, C Frenzel, WH Majoros, JTA Chi, ... Nature 450 (7172), 1096-1099, 2007 | 702 | 2007 |
| Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin S Aynacioglu, J Brockmöller, S Bauer, C Sachse, P Güzelbey, Z Öngen, ... British journal of clinical pharmacology 48 (3), 409-415, 1999 | 356 | 1999 |
| A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer C Sachse, G Smith, MJV Wilkie, JH Barrett, R Waxman, F Sullivan, ... Carcinogenesis 23 (11), 1839-1850, 2002 | 352 | 2002 |
| The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment J Brockmöller, J Kirchheiner, J Schmider, S Walter, C Sachse, ... Clinical Pharmacology & Therapeutics 72 (4), 438-452, 2002 | 305 | 2002 |
| Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and … C Sachse, U Bhambra, G Smith, TJ Lightfoot, JH Barrett, J Scollay, ... British journal of clinical pharmacology 55 (1), 68-76, 2003 | 259 | 2003 |
| Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies R Kittler, V Surendranath, AK Heninger, M Slabicki, M Theis, G Putz, ... Nature methods 4 (4), 337-344, 2007 | 237 | 2007 |
| Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population AS Aynacioglu, C Sachse, A Bozkurt, S Kortunay, M Nacak, T Schröder, ... Clinical Pharmacology & Therapeutics 66 (2), 185-192, 1999 | 228 | 1999 |
| Polymorphisms in xenobiotic conjugation and disease predisposition J Brockmöller, I Cascorbi, R Kerb, C Sachse, I Roots Toxicology letters 102, 173-183, 1998 | 117 | 1998 |
| miR-196 is an essential early-stage regulator of tail regeneration, upstream of key spinal cord patterning events T Sehm, C Sachse, C Frenzel, K Echeverri Developmental biology 334 (2), 468-480, 2009 | 115 | 2009 |
| Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer F Turner, G Smith, C Sachse, T Lightfoot, RC Garner, CR Wolf, D Forman, ... International journal of cancer 112 (2), 259-264, 2004 | 95 | 2004 |
| CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting S McElroy, J Richmond, M Lira, D Friedman, BM Silber, PM Milos, ... AAPS pharmsci 2, 1-11, 2000 | 94 | 2000 |
| Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine C Sachse, J Brockmöller, M Hildebrand, K Müller, I Roots Pharmacogenetics and Genomics 8 (2), 181-186, 1998 | 88 | 1998 |
| Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures D Schumacher, G Andrieux, K Boehnke, M Keil, A Silvestri, M Silvestrov, ... PLoS Genetics 15 (3), e1008076, 2019 | 70 | 2019 |
| Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism C Sachse, S Ruschen, M Dettling, J Schley, S Bauer, ... Clinical Pharmacology & Therapeutics 66 (4), 431-438, 1999 | 70 | 1999 |
| Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in-and outpatients M Dettling, C Sachse, J Brockmöller, J Schley, B Müller-Oerlinghausen, ... Psychopharmacology 152, 80-86, 2000 | 68 | 2000 |
| Oncology studies using siRNA libraries: the dawn of RNAi-based genomics C Sachse, CJ Echeverri Oncogene 23 (51), 8384-8391, 2004 | 67 | 2004 |
| Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation KJ Aitchison, J Munro, P Wright, S Smith, AJ Makoff, C Sachse, PC Sham, ... British journal of clinical pharmacology 48 (3), 388-394, 1999 | 63 | 1999 |
| High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: functional genomics investigations of biological pathways C Sachse, E Krausz, A Krönke, M Hannus, A Walsh, A Grabner, ... Methods in enzymology 392, 242-277, 2005 | 59 | 2005 |
